1. Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome 
Carla M. Davis, MD, Vikas S. Kancherla, MD, Ashwini Reddy, MD, Wenyaw Chan, PhD, Hung-Wen Yeh, PhD, Lenora M. Noroski, MD, Howard Rosenblatt, MD, William T. Shearer, MD, PhD, Javier Chinen, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 122, Issue 6, Pages (December 2008)
DOI: /j.jaci
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
CD3 T-cell absolute counts at baseline presentation. Diamonds represent individual values. Lines represent values for age-matched healthy control subjects, as indicated.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Slow decrease of CD3 T-cell counts over time. All obtained values (456 points) from 93 patients with pDGS are plotted. Data points per patient range from 1 to 21. The red line represents the overall trend calculated by using the multiple mixed linear model. A, CD3 T-cell absolute counts (in cells per cubic millimeter). B, CD3 T-cell percentages (CD3 T-cell count/total lymphocyte number).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Conserved mitogen (PHA)–stimulated lymphocyte proliferation (cpm) progress over time after baseline presentation. Available results obtained from all 93 patients are presented (438 points). Points per patient range from 1 to 19. Available results obtained from all patients are presented. The red line represents overall trend, according to the multiple mixed linear model.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Fig 4
Conserved mitogen (PHA)–stimulated lymphocyte proliferation (cpm) trends over time after baseline presentation in patient groups stratified by baseline CD3 lymphocyte counts (<10th percentile [dashed line], 10th-50th percentile [dotted line], and >50th percentile [solid line] of published normal values).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Fig 5
Increasing antigen-specific stimulated lymphocyte proliferation over time. All obtained values (443 points) from 93 patients are plotted. Data points per patient range from 1 to 19. The red line represents overall trend, according to the multiple mixed linear model. A, Candida antigen–stimulated lymphocyte proliferation (cpm). B, Candida antigen–stimulated lymphocyte proliferation (SI). C, Tetanus-stimulated lymphocyte proliferation (cpm). D, Tetanus-stimulated lymphocyte proliferation (SI).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7. Fig 6
Increasing antigen-specific stimulated lymphocyte proliferation (SI) trends over time after baseline presentation in patient groups stratified by baseline CD3 lymphocyte counts (<10th percentile [dotted line], 10th-50th percentile [dashed line], and >50th percentile [solid line] of published age-matched normal values). A, Candida antigen–specific lymphoproliferative response. B, Tetanus-specific lymphoproliferative response.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8. Fig 7
Development of cellular immunity to Candida antigen and tetanus after 3 tetanus immunizations. A, Cumulative percentage of vaccinated patients having immunity to antigens. B, Percentage of vaccinated patients with lymphocyte proliferation to antigens (SI >3 and cpm >1000). Ideal indicates persistent immunity, transient indicates the development of antigen immune responses with subsequent loss, and incomplete indicates the lack of development of immunity.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions